StemCell Therapy

INTRODUCTION:

Pain control is one of the most important aspects ofrheumatoid arthritis(RA) management from the patients perspective. Newer generations of RA treatment including tumor necrosis factor inhibitor (TNFi) have the potential to alleviate pain and thus reduce opioid utilization. However, patterns of opioid utilization before and after TNFi initiation have not been well characterized. This study aims to examine multiple measures of change in opioid utilization after the initiation of TNFi.

Patients aged 18years with RA and 24months continuous enrollment between January 2007 and December 2015 who newly initiated a TNFi in IQVIA Health Plan Claims Data were included in our study. Opioid utilization at baseline and during follow-up were identified and compared.

Of 2330 patients with RAthat were included in the study, 38.8% of patients used opioids in both baseline and follow-up periods. From pre-index to post-index, the proportion of patients receiving any opioid decreased from 54.0 to 51.0%. In addition, the proportion of those who received 50mg median daily MED decreased from 12.6 to 10.6% during pre-post periods.

This real-world study of commercially insured patients with RA suggests that opioid use among thesepatients is prevalent. There was a small decrease in overall opioid utilization after TNFi initiation.

See more here:
Changes in Opioid Utilization Following Tumor Necrosis Factor Inhibitor Initiation in Patients with Rheumatoid Arthritis - DocWire News

This entry was posted on November 5, 2019 at 2:44 pm and is filed under Arthritis. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |